RBV Capital is a specialized venture fund established in 2014 with the participation of R-Pharm JSC and RVC JSC to invest in innovative biomedical companies all over the world. BV Capital creates a diversified portfolio of breakthrough projects at the early development stages at the leading foreign markets and in Russia. The fund investment strategy is focused on the advanced scientific developments aimed to solve the major medical problems. RBV Capital has a number of successful foreign market entering.
ITMO is a major state technical university in St. Petersburg, one of the national research universities in Russia, a participant in the university’s “5 in 100” program.
The university’s scientific priorities are information and photon technologies.
University ITMO develops fundamental and applied research, striving to unite science and business. The University makes every effort to ensure that advanced scientific developments are successfully brought to the market, and business needs have been heard by scientists and developers.
Also, there is a techno park in the ITMO university. AGCT company is a resident of this park.
Pavlov First Saint Petersburg State Medical University – is one of the leading Russian medical universities, where besides the academic buildings the most powerful clinical bases, scientific and research laboratories are concentrated. For more than 100 years, doctors and university students have made a significant contribution to the development of medicine and the maintenance of public health. And during this time the university confidently took a place in the European medical tradition as one of the most popular medical and scientific schools.
Scientific Research Institute of Oncology – is one of the largest specialized medical and diagnostic centers and the leading scientific oncological institution in the North-West of Russia. In the clinics of the Institute there is a specialized, including high-tech medical care at the level of world standards. Annually about 100 000 patients from different regions of Russia and CIS countries receive in-patient and consultative-diagnostic assistance.
The research activity of the Institute is aimed at developing methods for the prevention, diagnosis and treatment of cancer.
Skolkovo is located in Moscow, a modern scientific and technological innovation complex for the development and commercialization of new technologies, representing a point of crystallization around which the country’s innovative potential is being formed. Skolkovo is a unique platform, which allows to broadcast breakthrough scientific developments from the laboratory into application in practical medicine.
The unit is part of the Pavlov First Saint Petersburg State Medical University, specializing in helping patients with the most unfavorable and resistant to standard therapy severe forms of oncohematological and hereditary diseases. It is the only medical institution in the Russian Federation that is a member of the European Bone Marrow Transplantation Society and is accredited by the American Bone Marrow Transplantation Group.
Institution is one of the largest transplant centers in Europe, about 300 transplantations of hemopoietic cells are carried out in its clinic annually, including the most complex ones (transplants from unrelated and partially compatible donors). On the basis of the Institute, a Russian register of stem cell and bone marrow donors is being created. Various, including fundamental, studies are under way.
All of members of the AGCT company team are employees of the Raisa Gorbacheva Memorial Institute of Children’s Oncology, Hematology and Transplantation